Associations - Diffuse Large B Cell Lymphoma

No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Sensitive: C1 - Off-label ICML 2021 - 1 week
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	GEN3013 Sensitive: C2 – Inclusion Criteria ICML 2021 - 1 week
CD20 overexpression CD20 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 1 week
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: C3 – Early Trials ICML 2021 - 1 week
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: C3 – Early Trials ICML 2021 - 1 week
PAX5 mutation PAX5 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 1 week
CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 1 week
EP300 mutation EP300 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 1 week
TBX21 overexpression TBX21 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials ICML 2021 - 1 week
PD-L1 amplification PD-L1 amplification	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	atezolizumab Sensitive: C3 – Early Trials ICML 2021 - 1 week
SOCS1 mutation SOCS1 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 1 week
IRF8 mutation IRF8 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 1 week
CD19 mutation CD19 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 1 week
CD58 mutation CD58 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 1 week
TIGIT overexpression TIGIT overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials ICML 2021 - 1 week
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	C-RICE Sensitive: C3 – Early Trials ICML 2021 - 1 week
MYC rearrangement + BCL6 rearrangement MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	C-RICE Sensitive: C3 – Early Trials ICML 2021 - 1 week
CLTC-ALK fusion CLTC-ALK fusion	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	arsenic trioxide Sensitive: D – Preclinical Br J Haematol - 1 week
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical ICML 2021 - 1 week
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical ICML 2021 - 1 week
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical ICML 2021 - 1 week
CD24 overexpression CD24 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials Dovepress - 3 weeks
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval
No biomarker No biomarker	Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	Truxima (rituximab biosimilar) Sensitive: A1 - Approval
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	selinexor Sensitive: A1 - Approval
No biomarker No biomarker	Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab/hyaluronidase Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	polatuzumab vedotin Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: A2 - Guideline
No biomarker No biomarker	Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma	rituximab Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MINE Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-GemOx Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	GemOx Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ESHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ICE Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	RICE Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	GDP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	RGDP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	DHAX Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	DHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-DHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	EPOCH-R Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	CEOP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	CEPP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-ESHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-GCVP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CEOP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CEPP Sensitive: A2 - Guideline
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CDOP Sensitive: A2 - Guideline
MYC rearrangement + BCL6 rearrangement MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline
No biomarker No biomarker	Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline
MYC overexpression + BCL2 overexpression MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials
MYC rearrangement MYC rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials
LDH elevation LDH elevation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ALLO-501A Sensitive: B - Late Trials
EZH2 mutation EZH2 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label
TNFRSF8 positive TNFRSF8 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: C1 - Off-label
BCL2 expression BCL2 expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria
MYC expression MYC expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	RG6146 Sensitive: C2 – Inclusion Criteria
BIRC5 expression BIRC5 expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	pembrolizumab + maveropepimut-S Sensitive: C2 – Inclusion Criteria
MYC rearrangement MYC rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
BCL6 rearrangement BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
BCL2 rearrangement BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Sensitive: C2 – Inclusion Criteria
TNFRSF8 expression TNFRSF8 expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + brentuximab vedotin Sensitive: C2 – Inclusion Criteria
MYC overexpression MYC overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Resistant: C3 – Early Trials
MYC negative MYC negative	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: C3 – Early Trials
MYC positive MYC positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: C3 – Early Trials
MAD2L2 overexpression MAD2L2 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials
CRTAM overexpression CRTAM overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
BTLA overexpression BTLA overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
LEF1 overexpression LEF1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
KLHL14 mutation KLHL14 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
LRP1B mutation LRP1B mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials
BCL2 positive BCL2 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials
BCL2 expression + MYC expression BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	methotrexate Resistant: C3 – Early Trials
BCL2 expression + MYC expression BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials
BCL2 rearrangement BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	EPOCH-R Sensitive: C3 – Early Trials
LDH elevation LDH elevation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ViPOR Sensitive: C3 – Early Trials
BCL6 translocation BCL6 translocation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials
BCL2 expression + MYC expression BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
MYC translocation + BCL2 translocation MYC translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials
MYC translocation + BCL6 translocation MYC translocation + BCL6 translocation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials
MYC positive + BCL2 positive MYC positive + BCL2 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials
MYC positive + BCL2 positive + BCL6 positive MYC positive + BCL2 positive + BCL6 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials
BCL2 amplification BCL2 amplification	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
BCL2 positive BCL2 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	venetoclax Sensitive: C3 – Early Trials
MYC overexpression + BCL2 overexpression MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials
CD34 underexpression CD34 underexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials
MYD88 L265P + CD79B mutation MYD88 L265P + CD79B mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials
miR-6860-5p expression miR-6860-5p expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Resistant: C3 – Early Trials
TP53 expression TP53 expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
miR-193b-5p expression miR-193b-5p expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials
miR-199a-5p expression miR-199a-5p expression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

Diffuse Large B Cell Lymphoma

Associations(237)

Associations
(237)